{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:48:00Z","timestamp":1788457680499,"version":"build-2803163510"},"reference-count":115,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hereditary transthyretin amyloidosis with peripheral neuropathy (ATTRv-PN) is an autosomal dominant inherited sensorimotor and autonomic polyneuropathy with over 130 pathogenic variants identified in the TTR gene. Hereditary transthyretin amyloidosis with peripheral neuropathy is a disabling, progressive and life-threatening genetic condition that leads to death in \u223c 10 years if untreated. The prospects for ATTRv-PN have changed in the last decades, as it has become a treatable neuropathy. In addition to liver transplantation, initiated in 1990, there are now at least 3 drugs approved in many countries, including Brazil, and many more are being developed. The first Brazilian consensus on ATTRv-PN was held in the city of Fortaleza, Brazil, in June 2017. Given the new advances in the area over the last 5 years, the Peripheral Neuropathy Scientific Department of the Brazilian Academy of Neurology organized a second edition of the consensus. Each panelist was responsible for reviewing the literature and updating a section of the previous paper. Thereafter, the 18 panelists got together virtually after careful review of the draft, discussed each section of the text, and reached a consensus for the final version of the manuscript.<\/jats:p>","DOI":"10.1055\/s-0043-1764412","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T23:57:07Z","timestamp":1681516627000},"page":"308-321","source":"Crossref","is-referenced-by-count":15,"title":["Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition"],"prefix":"10.1055","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-6657","authenticated-orcid":false,"given":"Marcus Vinicius","family":"Pinto","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Hospital Universit\u00e1rio Clementino Fraga Filho, Centro de Estudos em Paramiloidose Ant\u00f4nio Rodrigues de Mello, Rio de Janeiro RJ, Brazil."},{"name":"Mayo Clinic, Department of Neurology, Rochester, Minnesota, United States."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-2419","authenticated-orcid":false,"suffix":"Jr","given":"Marcondes Cavalcante","family":"Fran\u00e7a","sequence":"additional","affiliation":[{"name":"Universidade de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9127-7886","authenticated-orcid":false,"given":"Marcus Vinicius Magno","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Universidade Univalle, Joinville SC, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6987-3086","authenticated-orcid":false,"given":"Marcela C\u00e2mara","family":"Machado-Costa","sequence":"additional","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica, Salvador, BA, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-0287","authenticated-orcid":false,"given":"Marcos Raimundo Gomes de","family":"Freitas","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Hospital Universit\u00e1rio Clementino Fraga Filho, Centro de Estudos em Paramiloidose Ant\u00f4nio Rodrigues de Mello, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8957-5796","authenticated-orcid":false,"given":"Francisco de Assis Aquino","family":"Gondim","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1, Faculdade de Medicina, Fortaleza CE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0092-4775","authenticated-orcid":false,"given":"Carlo Domenico","family":"Marrone","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Hospital S\u00e3o Lucas, Cl\u00ednica Marrone e Ambulat\u00f3rio de Doen\u00e7as Neuromusculare, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7160-0853","authenticated-orcid":false,"given":"Alberto Rolim Muro","family":"Martinez","sequence":"additional","affiliation":[{"name":"Universidade de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1819-7801","authenticated-orcid":false,"given":"Carolina Lavigne","family":"Moreira","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3516-485X","authenticated-orcid":false,"given":"Osvaldo J. M.","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Niter\u00f3i RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-8070","authenticated-orcid":false,"given":"Anna Paula Paranhos","family":"Covaleski","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Hospital das Cl\u00ednicas, Recife PE, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-4937","authenticated-orcid":false,"given":"Acary Souza Bulle de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, Escola Paulista de Medicina, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9590-435X","authenticated-orcid":false,"given":"Camila Castelo Branco","family":"Pupe","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense, Niter\u00f3i RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-6857","authenticated-orcid":false,"given":"Marcia Maria Jardim","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9954-191X","authenticated-orcid":false,"given":"Francisco Tellechea","family":"Rotta","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento, Porto Alegre RS, Brazil."},{"name":"Santa Casa de Miseric\u00f3rdia de Porto Alegre, Porto Alegre RS, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-5317","authenticated-orcid":false,"given":"Rosana Herminia","family":"Scola","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Faculdade de Medicina, Curitiba PR, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-2749","authenticated-orcid":false,"suffix":"Jr","given":"Wilson","family":"Marques","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-2236","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Waddington-Cruz","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro, Hospital Universit\u00e1rio Clementino Fraga Filho, Centro de Estudos em Paramiloidose Ant\u00f4nio Rodrigues de Mello, Rio de Janeiro RJ, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade","volume":"86","author":"F Chiti","year":"2017","journal-title":"Annu Rev Biochem"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"M D Benson","year":"2018","journal-title":"Amyloid"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy","volume":"36","author":"M D Benson","year":"2007","journal-title":"Muscle Nerve"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"V Plant\u00e9-Bordeneuve","year":"2011","journal-title":"Lancet Neurol"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"D Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"F L Ruberg","year":"2012","journal-title":"Circulation"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"D Adams","year":"2021","journal-title":"J Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care","volume":"16","author":"M Luigetti","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/brain\/123.7.1495","article-title":"The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation","volume":"123","author":"D Adams","year":"2000","journal-title":"Brain"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"T Coelho","year":"2012","journal-title":"Neurology"},{"issue":"24","key":"ref11","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"J L Berk","year":"2013","journal-title":"JAMA"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"D Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"M D Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1590\/0004-282x20180094","article-title":"Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy","volume":"76","author":"M V Pinto","year":"2018","journal-title":"Arq Neuropsiquiatr"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Y Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13506129.2017.1292903","article-title":"Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review","volume":"24","author":"H Schmidt","year":"2017","journal-title":"Amyloid"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Y Parman","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study","volume":"51","author":"M In\u00eas","year":"2018","journal-title":"Neuroepidemiology"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review","volume":"324","author":"M A Gertz","year":"2020","journal-title":"JAMA"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.1320600606","article-title":"Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in P\u00f3voa do Varzim and Vila do Conde (north of Portugal)","volume":"60","author":"A Sousa","year":"1995","journal-title":"Am J Med Genet"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"U Hellman","year":"2008","journal-title":"Amyloid"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1136\/jmg.40.11.e120","article-title":"Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families","volume":"40","author":"V Plant\u00e9-Bordeneuve","year":"2003","journal-title":"J Med Genet"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1468-1331.2008.02429.x","article-title":"Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families","volume":"16","author":"M A Saporta","year":"2009","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-019-1000-1","article-title":"Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series","volume":"14","author":"M Waddington-Cruz","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/jns.12259","article-title":"The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population","volume":"23","author":"C Lavigne-Moreira","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/brain\/122.10.1951","article-title":"Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features","volume":"122","author":"Ki Misu","year":"1999","journal-title":"Brain"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/brain\/113.4.903","article-title":"Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system","volume":"113","author":"G Sobue","year":"1990","journal-title":"Brain"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Y Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"P Hammarstr\u00f6m","year":"2001","journal-title":"Science"},{"issue":"08","key":"ref32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/ejhg.2010.36","article-title":"TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?","volume":"18","author":"B Bona\u00efti","year":"2010","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"H Koike","year":"2002","journal-title":"Arch Neurol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/TCRM.S185677","article-title":"Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines","volume":"16","author":"M D Benson","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/nmt-2019-0020","article-title":"Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease","volume":"9","author":"V E Thomas","year":"2019","journal-title":"Neurodegener Dis Manag"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1590\/0004-282x20180156","article-title":"Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"77","author":"M W Cruz","year":"2019","journal-title":"Arq Neuropsiquiatr"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s004390050199","article-title":"Revised transthyretin Ile 122 allele frequency in African-Americans","volume":"98","author":"D R Jacobson","year":"1996","journal-title":"Hum Genet"},{"key":"ref38","first-page":"88","volume-title":"Forty years of experience with type I amyloid neuropathy: review of 483 cases","author":"P DA Coutinho","year":"1980"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/13506129.2012.673183","article-title":"Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil","volume":"19","author":"M W Cruz","year":"2012","journal-title":"Amyloid"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2004.00941.x","article-title":"Phenotypic expression of familial amyloid polyneuropathy in Brazil","volume":"12","author":"P L Bittencourt","year":"2005","journal-title":"Eur J Neurol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2019.05.030","article-title":"Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry","volume":"403","author":"M V Pinto","year":"2019","journal-title":"J Neurol Sci"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"I Concei\u00e7\u00e3o","year":"2007","journal-title":"Muscle Nerve"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"L L Mariani","year":"2015","journal-title":"Ann Neurol"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"H Koike","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","article-title":"Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy","volume":"260","author":"M F Dohrn","year":"2013","journal-title":"J Neurol"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","article-title":"Hereditary ATTR amyloidosis: a single-institution experience with 266 patients","volume":"22","author":"P L Swiecicki","year":"2015","journal-title":"Amyloid"},{"issue":"03","key":"ref47","first-page":"408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"C Andrade","year":"1952","journal-title":"Brain"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transthyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Y Ando","year":"2005","journal-title":"Arch Neurol"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.31.4.293","article-title":"A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected","volume":"31","author":"T Coelho","year":"1994","journal-title":"J Med Genet"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/brain\/110.2.315","article-title":"Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients","volume":"110","author":"S Ikeda","year":"1987","journal-title":"Brain"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/13506129.2012.685665","article-title":"Regional difference and similarity of familial amyloidosis with polyneuropathy in France","volume":"19","author":"D Adams","year":"2012","journal-title":"Amyloid"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"C Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"H Yamamoto","year":"2019","journal-title":"ESC Heart Fail"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"M S Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"ref55","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"P Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"05","key":"ref56","first-page":"503","article-title":"Frequency of Cardiovascular Involvement in Familial Amyloidotic Polyneuropathy in Brazilian Patients","volume":"105","author":"M C Queiroz","year":"2015","journal-title":"Arq Bras Cardiol"},{"issue":"24","key":"ref57","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"J D Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.36660\/abc.20210718","article-title":"Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021","volume":"117","author":"M V Sim\u00f5es","year":"2021","journal-title":"Arq Bras Cardiol"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mus.20185","article-title":"Muscular amyloid angiopathy with amyloidgenic transthyretin Ser50Ile and Tyr114Cys","volume":"31","author":"T Yamashita","year":"2005","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mus.26723","article-title":"Transthyretin amyloidosis: Putting myopathy on the map","volume":"61","author":"M V Pinto","year":"2020","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/mus.27150","article-title":"Neuromuscular amyloidosis: Unmasking the master of disguise","volume":"64","author":"M V Pinto","year":"2021","journal-title":"Muscle Nerve"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/bjo.81.4.295","article-title":"Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up","volume":"81","author":"E Ando","year":"1997","journal-title":"Br J Ophthalmol"},{"issue":"05","key":"ref63","first-page":"528","article-title":"Ophthalmological manifestations of hereditary transthyretin amyloidosis","volume":"85","author":"F AA Gondim","year":"2022","journal-title":"Arq Bras Oftalmol"},{"issue":"08","key":"ref64","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"L Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13506129.2019.1600497","article-title":"Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis","volume":"26","author":"S I Ikeda","year":"2019","journal-title":"Amyloid"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","article-title":"CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings","volume":"86","author":"L F Maia","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"24","key":"ref67","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.0000000000012965","article-title":"CNS Involvement in Hereditary Transthyretin Amyloidosis","volume":"97","author":"L Sousa","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"ref68","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnen\/nlaa075","article-title":"Oculoleptomeningeal Amyloidosis Due to Transthyretin p.Y89H (Y69H) Variant","volume":"79","author":"G S Quintanilha","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"D Adams","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"04","key":"ref71","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1085-9489.2004.09405.x","article-title":"Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies","volume":"9","author":"C Vital","year":"2004","journal-title":"J Peripher Nerv Syst"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/13506120903421850","article-title":"Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type","volume":"16","author":"B Do Amaral","year":"2009","journal-title":"Amyloid"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10072-016-2760-1","article-title":"Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy","volume":"38","author":"F de Paula Eduardo","year":"2017","journal-title":"Neurol Sci"},{"issue":"24","key":"ref74","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"C C Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"02","key":"ref75","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13506129.2011.565524","article-title":"Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis","volume":"18","author":"H Koike","year":"2011","journal-title":"Amyloid"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"L Obici","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"05","key":"ref77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy","volume":"88","author":"A Cortese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/practneurol-2018-002098","article-title":"Diagnosis of amyloid neuropathy","volume":"19","author":"M Kapoor","year":"2019","journal-title":"Pract Neurol"},{"issue":"07","key":"ref79","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"V Plant\u00e9-Bordeneuve","year":"2007","journal-title":"Neurology"},{"issue":"06","key":"ref80","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/14656566.2016.1145664","article-title":"TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies","volume":"17","author":"D Adams","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"S 01","key":"ref81","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","article-title":"Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis","volume":"29","author":"L Obici","year":"2019","journal-title":"Clin Auton Res"},{"issue":"S 01","key":"ref82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10286-019-00627-7","article-title":"Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis","volume":"29","author":"I Bentellis","year":"2019","journal-title":"Clin Auton Res"},{"issue":"02","key":"ref83","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10286-018-0514-2","article-title":"Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis)","volume":"29","author":"A Gonzalez-Duarte","year":"2019","journal-title":"Clin Auton Res"},{"issue":"19","key":"ref84","doi-asserted-by":"crossref","first-page":"e016614","DOI":"10.1161\/JAHA.120.016614","article-title":"Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations","volume":"9","author":"N Marques","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"ref85","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"F L Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Y Ando","year":"2022","journal-title":"Amyloid"},{"issue":"03","key":"ref87","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"A Carvalho","year":"2015","journal-title":"Liver Transpl"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)","volume":"40","author":"G Holmgren","year":"1991","journal-title":"Clin Genet"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/jlts.2002.29764","article-title":"Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil","volume":"8","author":"P L Bittencourt","year":"2002","journal-title":"Liver Transpl"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis","volume":"341","author":"G Holmgren","year":"1993","journal-title":"Lancet"},{"issue":"09","key":"ref91","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00007890-199511150-00009","article-title":"Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients","volume":"60","author":"O B Suhr","year":"1995","journal-title":"Transplantation"},{"issue":"09","key":"ref92","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?","volume":"99","author":"B G Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"01","key":"ref93","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13506129.2014.989318","article-title":"Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis","volume":"22","author":"J M Beir\u00e3o","year":"2015","journal-title":"Amyloid"},{"issue":"07","key":"ref94","doi-asserted-by":"crossref","first-page":"e1088","DOI":"10.1212\/WNL.0000000000011289","article-title":"Pearls & Oy-sters: Number, Weaker, and Dizzier Due to Transthyretin Amyloidosis After 2 Liver Transplants","volume":"96","author":"A I Yerevanian","year":"2021","journal-title":"Neurology"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis","volume":"5","author":"T Coelho","year":"2016","journal-title":"Neurol Ther"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40120-015-0031-3","article-title":"A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis","volume":"4","author":"M Waddington Cruz","year":"2015","journal-title":"Neurol Ther"},{"issue":"11","key":"ref97","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"T Coelho","year":"2013","journal-title":"J Neurol"},{"issue":"03","key":"ref98","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"M Waddington Cruz","year":"2016","journal-title":"Amyloid"},{"issue":"01","key":"ref99","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13023-018-0947-7","article-title":"Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy","volume":"13","author":"L Amass","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"03","key":"ref100","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"F A Barroso","year":"2017","journal-title":"Amyloid"},{"issue":"06","key":"ref101","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"G Merlini","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"issue":"03","key":"ref102","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ene.13510","article-title":"Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy","volume":"25","author":"B K Gundapaneni","year":"2018","journal-title":"Eur J Neurol"},{"issue":"21","key":"ref103","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"T Coelho","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"ref104","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"M S Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"02","key":"ref105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"T Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13506129.2019.1593133","article-title":"The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition","volume":"26","author":"J Wixner","year":"2019","journal-title":"Amyloid"},{"issue":"S 01","key":"ref108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/13506129.2012.673140","article-title":"Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy","volume":"19","author":"E J Ackermann","year":"2012","journal-title":"Amyloid"},{"issue":"03","key":"ref109","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides","volume":"23","author":"E J Ackermann","year":"2016","journal-title":"Amyloid"},{"issue":"08","key":"ref110","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/ene.14285","article-title":"Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial","volume":"27","author":"T H Brannagan","year":"2020","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref111","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy","volume":"10","author":"T Coelho","year":"2021","journal-title":"Neurol Ther"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"O B Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"01","key":"ref113","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"D Adams","year":"2021","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref114","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects","volume":"109","author":"B A Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"S 01","key":"ref115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"L Obici","year":"2012","journal-title":"Amyloid"},{"issue":"06","key":"ref116","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"J D Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"ref117","first-page":"e2783","article-title":"Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 emerging science abstracts. 2021 Emerging Science Abstracts","volume":"96","author":"O GM Suhr","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"ref118","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy","volume":"4","author":"C Monteiro","year":"2019","journal-title":"JCI Insight"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1764412.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T18:41:42Z","timestamp":1702233702000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1764412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":115,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,4,14]]},"published-print":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1764412","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}